Fig. 1 · Structure

Documents & Downloads

CFTR-Inhibitor-II

Cat. No. A13723 CAS 328541-79-3

CFTR inhibitor

CFTR inhibitor II, also known as GlyH-101, is a glycine hydrazide that selectively and reversibly blocks the CFTR channel (Ki = 4.3 uM).

In Stock

Publications for CFTR-Inhibitor-II

1 publication citing this product

  1. Dao-Lai Zhang, .et al. , eLife, 2018, 7: e33432 PMID: 29393851

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

GlyH-101 inhibits CFTR chloride current in a voltage-dependent manner. In human CFTR-expressing FRT cells, apparent Ki ranged from 1.4 ± 0.4 μM at +60 mV to 5.6 ± 0.4 μM at −60 mV. Current recovered after washout. Potency therefore depends on the electrical conditions of the assay. [1]

In a separate oocyte expression study, the CFTR F342A mutation lowered GlyH-101 EC50(0) from 1.1 ± 0.11 μM for wild type to 5.2 ± 0.83 nM. The functional result is consistent with GlyH-101 interaction within the CFTR pore, while the proposed binding pose remains a model. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
CFTR Ki 4.3 μM

CFTR-Inhibitor-II Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of CFTR-Inhibitor-II from 3 published references. In vitro models include fisher rat thyroid cells stably expressing wild-type human CFTR. In vivo models include mouse nasal epithelium in vivo.

CFTR-Inhibitor-II In Vitro Studies

GlyH-101 has CFTR-independent effects. In HEK293T cells without detectable CFTR, 10 μM GlyH-101 for 10 min reduced store-operated calcium entry. In a separate patch-clamp design, 50 μM inhibited Orai1/STIM1-mediated inward currents, whereas 0.5 and 5 μM did not significantly inhibit them. These findings limit attribution of cellular responses to CFTR alone; the calcium-entry and current assays used different exposure conditions. [3]

Voltage-dependent inhibition of human CFTR current

Cell-based study · Fisher rat thyroid cells stably expressing wild-type human CFTR [1]

Extracellular GlyH-101 inhibited forskolin-activated CFTR currents more potently at positive voltages. The current-voltage relationship recovered after washout. Apparent potency depends on assay voltage.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of CFTR chloride current at +60, +20, −20 and −60 mVApparent Ki 1.4 ± 0.4, 3.8 ± 0.2, 5.0 ± 0.3 and 5.6 ± 0.4 μM, respectively; mean ± SEM; four to five experiments per point[1]
Current-voltage relationship following removal of 10 μM GlyH-101Reversibility Recovered approximately linear current-voltage relationship after washout[1]

Literature-Reported Treatment Conditions

Treatment concentration
Dose-response: 0–50 μM; representative 10 and 30 μM conditions
Method
Extracellular perfusion during whole-cell patch clamp at room temperature
Co-treatment
CFTR activated with 5 μM forskolin
Reported limits
Exposure duration and final DMSO concentration for this patch-clamp experiment are not specified in the selected methods/caption.
Methods and source locations

Compound reported in the paper: GlyH-101; Compound label in the paper: GlyH-101

Compound-level research evidence; no Adooq lot, salt-equivalence or stereoisomer-specific validation.

Figure 5A-C; Patch-clamp Analysis of CFTR Inhibition Mechanism; patch-clamp methods

Inhibition of CFTR chloride current at +60, +20, −20 and −60 mV: Hill fit to whole-cell current inhibition — Figure 5C caption and Results

Current-voltage relationship following removal of 10 μM GlyH-101: Whole-cell recording; no-inhibitor, GlyH-101 and washout conditions — Figure 5B image/caption and Results

CFTR F342A mutation increases apparent GlyH-101 potency

Cell-based study · Xenopus laevis oocytes expressing wild-type or F342A CFTR together with human β2-adrenergic receptor [2]

The F342A mutant showed much lower voltage-adjusted EC50 than wild-type CFTR. This is functional evidence consistent with a pore binding model; it is not a direct structural determination of binding.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GlyH-101 inhibition of wild-type and F342A CFTR at 0 mVEC50(0) Wild type: 1.1 ± 0.11 μM (n = 4); F342A: 5.2 ± 0.83 nM (n = 3); mean ± SEM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Whole-cell methods specify 1 nM–100 μM across blockade measurements
Method
Extracellular application during two-electrode voltage clamp
Co-treatment
10 μM isoproterenol plus 1 mM IBMX stimulation
Reported limits
GlyH-101 supplier, final vehicle concentration and exposure time for the EC50 series are not specified in the selected methods.
Methods and source locations

Compound reported in the paper: GlyH-101; Compound label in the paper: GlyH-101

Compound-level research evidence; no Adooq lot, salt-equivalence or stereoisomer-specific validation.

Figure 1B-C and caption; Figure 8A and caption; Table 1 wild-type row; F342A Results; Whole-Cell Recordings and Reagents

GlyH-101 inhibition of wild-type and F342A CFTR at 0 mV: Dose-response fitting at each voltage followed by modified Woodhull analysis — Figure 1C caption; Table 1 wild-type row; Figure 8A caption and Results

CFTR-independent inhibition of store-operated calcium entry

Cell-based study · HEK293T cells with no detectable CFTR in the reported qPCR and immunoblot controls [3]

GlyH-101 reduced SOCE peak amplitude and rate in cells without detectable CFTR. DMSO controls and CFTR-expressing Calu-3 cells for expression controls support a CFTR-independent effect.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of SOCE peak amplitudeReported inhibition 38.5 ± 8.0%; p = 0.001 vs vehicle; Figure 2F n = 5–6 across groups[3]
Inhibition of initial SOCE rise rateReported inhibition 65.7 ± 7.3%; p = 0.002 vs vehicle; Figure 2F n = 5–6 across groups[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM GlyH-101
Exposure duration
10 min pretreatment before the second calcium addback
Method
Fura-2 calcium fluorimetry with repeated calcium addback
Vehicle
DMSO; methods keep DMSO ≤0.2%
Co-treatment
200 nM thapsigargin store depletion and 1 mM calcium addback
Reported limits
Exact DMSO concentration for this condition and whether the reported ± denotes SD or SEM are not specified.
Methods and source locations

Compound reported in the paper: GlyH-101; Compound label in the paper: GlyH-101

Compound-level research evidence; no Adooq lot, salt-equivalence or stereoisomer-specific validation.

Figure 2A-F; SOCE Results; Intracellular Ca2+ measurements; Chemicals; Statistics

Inhibition of SOCE peak amplitude: Second SOCE response compared with first; one-way ANOVA with Holm-Sidak comparisons; ± type unspecified — Results: CFTRinh-172 and GlyH-101 inhibit SOCE in epithelial cells that do not express CFTR; Figure 2F caption

Inhibition of initial SOCE rise rate: Linear regression of initial calcium rise; second vs first response; ± type unspecified — Same SOCE Results paragraph and Figure 2F caption

Concentration-dependent effects on Orai1/STIM1 currents

Cell-based study · HEK293T cells overexpressing Orai1/STIM1, compared with mock-transfected cells [3]

GlyH-101 significantly inhibited CPA-activated inward currents at 50 μM in Orai1/STIM1-expressing cells; lower concentrations did not significantly affect currents. Mock-transfected currents were unaffected. Docking did not reliably identify an Orai1 binding site.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CPA-activated inward currents, normalized at −100 mVConcentration-dependent inhibition Significant inhibition at 50 μM (p < 0.05); no significant effect at 0.5 or 5 μM; n = 6 per mock and Orai1/STIM1 group shown in figure[3]

Literature-Reported Treatment Conditions

Treatment concentration
0.5, 5 and 50 μM GlyH-101
Exposure duration
3 min at each concentration
Method
Fast whole-cell patch-clamp recordings
Vehicle
DMSO; methods keep DMSO ≤0.2%
Co-treatment
10 μM cyclopiazonic acid (CPA) maintained during inhibitor application
Reported limits
No IC50 or reliable molecular binding-site assignment was established.
Methods and source locations

Compound reported in the paper: GlyH-101; Compound label in the paper: GlyH-101

Compound-level research evidence; no Adooq lot, salt-equivalence or stereoisomer-specific validation.

Figure 3D-F; Orai1/STIM1 Results including docking limitation; Transfection; Whole cell patch clamp; Chemicals

CPA-activated inward currents, normalized at −100 mV: Whole-cell current measurement with mock-transfected controls; unpaired t-test as specified in caption — Figure 3D-F image/caption; Orai1/STIM1 Results

CFTR-Inhibitor-II In Vivo Studies

In mice, topical nasal perfusion with 10 μM GlyH-101 reversed forskolin-induced hyperpolarization. Continuous-inhibitor controls reduced the forskolin response while retaining the low-chloride response. This demonstrates an acute local electrophysiological effect and does not establish systemic or chronic efficacy. [1]

Acute inhibition of the mouse nasal CFTR response

Animal study · Mouse nasal epithelium in vivo [1]

Topical GlyH-101 reversed forskolin-induced nasal hyperpolarization. Separate continuous-inhibitor conditions reduced the forskolin response while retaining the low-chloride response. This is a local electrophysiological endpoint.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Forskolin-induced nasal potential difference and its reversalChange in potential difference Approximately 4 mV forskolin-induced hyperpolarization, reversed by a depolarization of similar magnitude; Figure 8A averages: mean ± SEM, n = 5[1]
Forskolin and low-chloride responses with inhibitor present throughoutControl comparison GlyH-101 reduced the forskolin-induced response (P < 0.005 vs control); low-chloride response was preserved[1]

Conditions shared by the study groups

Route
Topical nasal perfusion
Frequency
Acute sequential solution exchange
Vehicle
PBS-based nasal perfusion solutions
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Topical GlyH-101
10 μM in nasal perfusate
Within-recording forskolin-stimulated response before GlyH-101; separate control and DIDS conditions in Figure 8CReversal of forskolin-induced hyperpolarization; reduced forskolin response when GlyH-101 was present throughout[1]
Topical GlyH-101
Model: Mice undergoing nasal potential difference recording
Reported limits: Exact inhibitor exposure duration, strain and sex for the nasal cohort are not specified in the selected nasal methods/caption.
Methods and source locations

Compound reported in the paper: GlyH-101; Compound label in the paper: GlyH-101

Compound-level research evidence; no Adooq lot, salt-equivalence or stereoisomer-specific validation.

Figure 8A-C; CFTR Inhibition in Mice In Vivo; nasal PD methods

Forskolin-induced nasal potential difference and its reversal: Continuous nasal potential difference recording and paired response analysis — Figure 8A-B image/caption; CFTR Inhibition in Mice In Vivo Results

Forskolin and low-chloride responses with inhibitor present throughout: Separate continuous GlyH-101 or DIDS perfusion conditions — Figure 8C image/caption and Results

Topical GlyH-101 · Figure 8A-C; Nasal Potential Difference Measurements in Mice

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 328541-79-3
Applications CFTR inhibitor
Formula C19H15Br2N3O3
Molecular Weight 493.2
Synonyms GlyH-101; Cystic Fibrosis Transmembrane Conductance; Regulator Inhibitor II
SMILES
C1=CC=C2C=C(C=CC2=C1)NCC(=O)NN/C=C/3\C=C(C(=C(C3=O)Br)O)Br

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 91 mg/mL (184.53 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

CFTR-Inhibitor-II Research References

  1. [1] Chatchai Muanprasat, ND Sonawane, Danieli Salinas, et al. Discovery of Glycine Hydrazide Pore-occluding CFTR Inhibitors: Mechanism, Structure–Activity Analysis, and In Vivo Efficacy The Journal of General Physiology (2004). PMID: 15277574 DOI: 10.1085/jgp.200409059 Source material
  2. [2] Yohei Norimatsu, Anthony Ivetac, Christopher Alexander, et al. Locating a Plausible Binding Site for an Open-Channel Blocker, GlyH-101, in the Pore of the Cystic Fibrosis Transmembrane Conductance Regulator Molecular Pharmacology (2012). PMID: 22923500 DOI: 10.1124/mol.112.080267 Source material
  3. [3] JinHeng Lin, Sean M Gettings, Khaoula Talbi, et al. Pharmacological inhibitors of the cystic fibrosis transmembrane conductance regulator exert off-target effects on epithelial cation channels Pflugers Archiv (2023). PMID: 36205782 DOI: 10.1007/s00424-022-02758-9 Source material

Publications

1 publication citing this product

  1. Dao-Lai Zhang, .et al. , eLife, 2018, 7: e33432 PMID: 29393851

Added to your cart

View Cart Checkout
Loading...